Have we missed the bulk of the comeback rally in pharma stocks? Nithya Balasubramanian answers

“Sun, Cipla, Lupin being market leaders, should be able to do well. Most of these companies have actually added on the Street last year. While all those costs are in the P&L, we are expecting that this year, we will see their productivity improve.”